|
Prostate Cancer, Hereditary, 13
|
0.400 |
SusceptibilityMutation
|
disease |
CLINVAR |
|
|
|
|
Prostate Cancer, Hereditary, 13
|
0.400 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Chronic calcifying pancreatitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
It was concluded that PSP-S gene expression is specifically reduced in CCP patients.
|
2525567 |
1989 |
|
Nutrition Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Composition of calculi--at least 95% calcium salts and a degraded form of lithostathine S (formerly called PSP S2-5)--was similar in the Occidental alcoholic and in the tropical form: calcified calculi are probably related to alcohol and nutritional disorders.
|
1736346 |
1992 |
|
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Decreased expression of prostatic secretory protein PSP94 in prostate cancer.
|
7506990 |
1993 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Decreased expression of prostatic secretory protein PSP94 in prostate cancer.
|
7506990 |
1993 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Structural diversity in a 45 kDa surface antigen on Plasmodium falciparum merozoites (termed GYMSSA, MSP-2 or MSA-2) and other candidate molecules for developing a malaria vaccine need to be investigated in parasites obtained directly from patients in different malaria endemic countries.
|
7918680 |
1994 |
|
Liver Failure, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Decreased hepatic HGFL/MSP production might cause impaired Kupffer cell phagocytosis in fulminant hepatic failure.
|
7912298 |
1994 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
PSP94 has shown potential to be a serum biomarker for evaluating prostate cancer.
|
9136077 |
1997 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Prostate secretory protein of 94 amino acids (PSP94) has shown the potential to be a diagnostic biomarker and a therapeutic agent for prostate cancer.
|
9174167 |
1997 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
PSP94 is a potential biomarker for evaluating patients with prostate carcinoma.
|
9136076 |
1997 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
PSP94 has shown potential to be a serum biomarker for evaluating prostate cancer.
|
9136077 |
1997 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Prostate secretory protein of 94 amino acids (PSP94) has shown the potential to be a diagnostic biomarker and a therapeutic agent for prostate cancer.
|
9174167 |
1997 |
|
Complicated malaria
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
No specific genetic make-up was associated with severity; there were, however, marked differences in allele frequencies in both groups, with a prevalence up to 60% of MSP-2 alleles specifically observed in the severe malaria isolates.
|
9015525 |
1997 |
|
Carcinoid Tumor
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
HGFL/MSP mRNA is low to undetectable in human SCLC and carcinoid tumors, but the HGFL/MSP tyrosine kinase receptor, RON, is present and functional on many of these neuroendocrine tumors.
|
9185522 |
1997 |
|
Small cell carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
HGFL/MSP mRNA is low to undetectable in human SCLC and carcinoid tumors, but the HGFL/MSP tyrosine kinase receptor, RON, is present and functional on many of these neuroendocrine tumors.
|
9185522 |
1997 |
|
Neuroendocrine Tumors
|
0.010 |
AlteredExpression
|
group |
BEFREE |
HGFL/MSP mRNA is low to undetectable in human SCLC and carcinoid tumors, but the HGFL/MSP tyrosine kinase receptor, RON, is present and functional on many of these neuroendocrine tumors.
|
9185522 |
1997 |
|
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our results showed a lower level of expression of beta-MSP in prostate cancer tissue, compared with benign prostate tissue.
|
9568674 |
1998 |
|
Prostatic Neoplasms
|
0.570 |
AlteredExpression
|
group |
BEFREE |
We analyzed the expression of both beta-MSP mRNA and its protein in a large sample of prostate tumors from 104 patients with untreated prostate cancer, using both nonradioactive in situ hybridization (ISH) and IHC.
|
9568674 |
1998 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our results showed a lower level of expression of beta-MSP in prostate cancer tissue, compared with benign prostate tissue.
|
9568674 |
1998 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
MSP and RON could also constitute an autocrine/paracrine system in human NSCLC cell lines: five of 16 cell lines (squamous and adenosquamous) expressed both MSP and RON; and an additional five of 16 cell lines expressed RON without detectable MSP.
|
9533936 |
1998 |
|
Adenocarcinoma of prostate
|
0.020 |
Biomarker
|
disease |
BEFREE |
Detection of PSP94 and its specific binding sites in the prostate adenocarcinoma cell line LNCaP.
|
9817377 |
1998 |
|
Clinical malaria
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The finding of an association between reduced risk of clinical malaria and infection with parasites of merozoite surface protein 1 (MSP-1) type RO33 or MSP-2 type 3D7 further suggests that the concomitant immunity is, at least in part, a consequence of a response to these major merozoite surface proteins.
|
9463681 |
1998 |
|
Human anaplasmosis due to Anaplasma phagocytophilum
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Recombinant MSP-2B protein and an MSP-2A fusion protein were expressed in Escherichia coli and reacted with human sera positive for the HGE agent by immunofluorescence assay.
|
9673253 |
1998 |
|
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The presence of cells that express the beta-MSP transcript may be a novel indicator of potentially aggressive prostate cancer.
|
10075007 |
1999 |